Investigation of the combined efficacy of two Haemonchus contortus vaccines in weaner Merino sheep.

This study was conducted to investigate whether co-administration of Barbervax® (Bvax) with Haemonchus contortus surface larval antigen (HcsL3) would increase the protective efficacy and duration of protection against H. contortus infection in weaner Merino sheep. A total of 132 10-month-old weaned Merino ewe lambs were randomly allocated into six treatment groups (n = 22). Sheep were vaccinated four times with either Barbervax® (Bvax), H. contortus L3 surface larval antigen (HcsL3), combined vaccination (Bvax + HcsL3), Bvax + AlOH, HcsL3 + Saponin or remained as unvaccinated controls. Aluminium hydroxide (AlOH) and saponin adjuvants were included in HcsL3 and Bvax vaccines respectively. The first three vaccinations were given at 4 week intervals and the fourth vaccination provided as booster, 9 weeks later. All animals were treated with Zolvix™ (monepantel 25 mg/mL, Elanco) at the third vaccination and commencing two weeks later, artificially trickle infected with H. contortus L3. Worm egg count (WEC), packed cell volume (PCV), antibody titre and bodyweight were measured throughout the study as was specific antibody directed against each antigen using ELISA. The administration of Bvax and HcsL3, alone or in combination, induced an antibody response against HcsL3 but only the Bvax and the combined treatment elicited an antibody response to the Bvax antigen. The targeting of HcsL3 by each vaccine was confirmed by immunofluorescence staining of H. contortus L3. However, only the booster vaccination in the Bvax treatments reduced WEC to levels below untreated controls. The HcsL3 vaccine did not reduce WEC in this experiment and co-administration with Bvax did not improve the efficacy and duration of protection against H. contortus infection.

Protective efficacy of Barbervax® in Merino weaner sheep trickle infected with five doses of Haemonchus contortus infective larvae.

Barbervax® protects sheep against H. contortus infection; however, the level of protection afforded by the vaccine at different levels of larval challenge under field conditions has not been reported. Therefore, this study was designed to investigate the protective efficacy of Barbervax® at increasing doses of trickle infection with H. contortus third stage larvae (L3). Merino lambs (220) were randomly allocated to challenge treatment groups and received Barbervax® vaccinations at approximately 8, 11, 15 and 22 weeks of age or not vaccinated (control group). Animals within each treatment group were subjected to one of five levels of H. contortus L3 trickle infection (0, 300, 600, 1200 and 2400 L3/week in two split doses). Trickle infections started two weeks after the third vaccination (week 0). Worm egg count (WEC), packed cell volume (PCV), antibody titre and bodyweight were measured at week 2 (start of trickle infection), week 5 and then every two weeks for 11 weeks. Vaccinated weaners had a significantly (P < 0.0001) lower faecal WEC than unvaccinated control animals. Vaccination induced significant specific antibody responses that were not influenced by level of trickle infection. Vaccination significantly reduced the number of weaners requiring salvage anthelmintic treatment (9.4% vaccinated weaners versus 33.6% unvaccinated). Vaccine protective index based on WEC was similar at all challenge levels (overall mean> 60%) and at the higher challenge levels did not reduce H. contortus infection to levels that would not require anthelmintic treatment. Therefore, it is suggested that under conditions of high larval challenge the use of Barbervax® should be integrated with other control methods.

Evaluation of Barbervax® vaccination for lambing Merino ewes.

The Barbervax® vaccine, directed against Haemonchus contortus, has been commercially available in Australia since 2014. However, to date the optimal timing for booster vaccination of lambing ewes has not been identified. Therefore the aim of this experiment was to compare the efficacy of Barbervax® when administered to ewes one week prior to the commencement of lambing versus at lamb marking 7 weeks later. A total of 400 single bearing Merino ewes, run on a commercial sheep property in the New England region of New South Wales, previously primed with Barbervax® were enrolled in the project. The experiment incorporated a cross-over design with two treatments imposed pre-lambing; Barbervax® booster vaccination with anthelmintic (n = 200) or anthelmintic alone (n = 200). At lamb marking, there were four treatment groups (n = 100) and anthelmintic was administered to all treatment groups. The four treatment combinations were Barbervax® booster vaccination at pre-lambing and lamb marking (V-V), booster vaccination only at pre-lambing (V-A), booster vaccination only at lamb marking (A-V) or anthelmintic only at both at pre-lambing and lamb marking (A-A). Pre-lambing Barbervax® booster vaccination of ewes induced an antibody response and, when used in conjunction with anthelmintic, significantly reduced worm egg counts (WEC) assessed at 7 weeks (lamb marking) and 13 weeks later, relative to treatment with anthelmintic alone. Booster vaccination plus anthelmintic treatment at lamb marking was not effective at reducing WEC compared to anthelmintic treatment alone. Body weight and packed cell volume did not differ between the treatment groups throughout the trial. In conclusion Barbervax® booster vaccination at pre-lambing provides additional protection for reproducing ewes given an effective short acting anthelmintic at this time.